Reviews in Cardiovascular Medicine  2020, Vol. 21 Issue (1): 57-64     DOI: 10.31083/j.rcm.2020.01.577 Potential roles of microRNA-1 and microRNA-133 in cardiovascular disease Zhipeng Song1, Rui Gao2, Bo Yan3, 4, 5, *() 1 Department of Medicine, Shandong University School of Medicine, Jinan, Shandong, 250014, P. R. China
2 Cardiovascular Medicine Department, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, 272000, P. R. China
3 Shandong Provincial Key Laboratory of Cardiac Disease Diagnosis and Treatment, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, 272000,
P. R. China
4 Shandong Provincial Sino-US Cooperation Research Center for Translational Medicine, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, 272000, P. R. China
5 The Center for Molecular Genetics of Cardiovascular Diseases, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, 272000, P. R. China Abstract:

Cardiovascular disease is still the main cause of morbidity and mortality worldwide. Currently, the frontier of research into cardiovascular disease is the field of non-coding RNA. In this review, information was collected on the use of micro-RNAs as non-invasive biomarkers and their role in pathophysiological processes and therapeutic applications. In the case of microRNA-1 and microRNA-133, the roles and regulatory mechanisms of them are reviewed for arrhythmia, myocardial infarction, diabetic cardiomyopathy, myocardial hypertrophy, cardiomyocyte differentiation, and cell reprogramming. It was observed that microRNA-1 and microRNA-133 do not exist independently, but are two co-transcriptional and cooperative regulatory factors. They have diagnostic value as biomarkers, but also have the potential as therapeutic targets such as for antiarrhythmia and cardiac reprogramming.

Submitted:  15 October 2019      Accepted:  14 February 2020      Published:  30 March 2020      Fund: 
81870279/National Natural Science Foundation of China *Corresponding Author(s):  Bo Yan     E-mail:  yanbo@mail.jnmc.edu.cn Service E-mail this article Add to citation manager E-mail Alert RSS Articles by authors Zhipeng Song    Rui Gao    Bo Yan   

Figure 1.  Model of miR-1 and miR-133-mediated regulation of arrhythmia. MiR-1 and miR-133 co-regulate arrhythmia. The red dotted line indicates the regulation that needs to be verified. AA, arachidonic acid; CYP450, Cytochrome P450; EETs, epoxyeicosatrienoic acids; sEH, soluble epoxide hydrolase; sEHi, soluble epoxide hydrolase inhibitor; DHETs, dihydroxyeicosatrienoic acids; miR-133, microRNA-133; KCNQ1, potassium voltage-gated channel subfamily Q member 1; IKs, slow delayed rectifier K+ current; KCNH2, potassium voltage-gated channel subfamily H member 2; ERG, ether-a-go-go related gene; IKr, delayed rectifier K+ current; miR-1, microRNA-1; KCNJ2, potassium voltage-gated channel subfamily J member 2; Kir2.1, inwardly rectifying K channel 2.1; GJA1, gap junction protein alpha 1; Cx43, connexin 43.

Figure 2.  Model of miR-1 and miR-133-mediated regulation of myocardial hypertrophy and cell differentiation. MiR-1 and miR-133 regulate myocardial hypertrophy and cell differentiation synergistically. The black dotted line indicates indirect regulation, and the red dotted line indicates the regulation that needs to be verified. miR-133, microRNA-133; SRF, serum response factor; CArG, [CC (A/T) 6GG]; GATA4, GATA binding protein 4; miR-1, microRNA-1; Ca, Calcium; CaM, calcium-binding protein calmodulin; CN, calcineurin; NFAT, nuclear factor of the activated T cell; CaMK, calcium-calmodulin dependent protein kinase; MEF2a, myocyte enhancer factor 2a; HDAC4, histone deacetylase 4; MEF2, myocyte enhancer factor 2; MyoD, myogenic determination factor.

[1] Afzal, M.R.,Samanta, A.,Shah, Z.I.,Jeevanantham, V.,Abdel-Latif, A.,Zuba-Surma, E.K. and Dawn, B. (2015)Adult bone marrow cell therapy for ischemic heart disease: evidence and insights from randomized controlled trials.Circulation Research 117, 558-575. [2] Arroyo, J.D.,Chevillet, J.R.,Kroh, E.M.,Ruf, I.K.,Pritchard, C.C.,Gibson, D.F.,Mitchell, P.S.,Bennett, C.F.,Pogosova-Agadjanyan, E.L.,Stirewalt, D.L.,Tait, J.F. and Tewari, M. (2011)Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma.Proceedings of the National Academy of Sciences 108, 5003-5008. [3] Besser, J.,Malan, D.,Wystub, K.,Bachmann, A.,Wietelmann, A.,Sasse, P.,Fleischmann, B.K.,Braun, T. and Boettger, T. (2014)MiRNA-1/133a clusters regulate adrenergic control of cardiac repolarization.PLOS ONE 9, e113449. [4] Carè, A.,Catalucci, D.,Felicetti, F.,Bonci, D.,Addario, A.,Gallo, P.,Bang, M.L.,Segnalini, P.,Gu, Y.,Dalton, N.D.,Elia, L. and Latronico, M.V. (2007)MicroRNA-133 controls cardiac hypertrophy.Nature Medicine 13, 613-618. [5] Cheng, M.,Yang, J.,Zhao, X.,Zhang, E.,Zeng, Q.,Yu, Y.,Yang, L.,Wu, B.,Yi, G.,Mao, X.,Huang, K.,Dong, N.,Xie, M.,Limdi, N.A.,Prabhu, S.D.,Zhang, J. and Qin, G. (2019)Circulating myocardial microRNAs from infarcted hearts are carried in exosomes and mobilise bone marrow progenitor cells.Nature Communications 10, 959. [6] Cheng, M.,Zhou, J.,Wu, M.,Boriboun, C.,Thorne, T.,Liu, T.,Xiang, Z.,Zeng, Q.,Tanaka, T.,Tang, Y.L.,Kishore, R.,Tomasson, M.H.,Miller, R.J.,Losordo, D.W. and Qin, G. (2010)CXCR4-mediated bone marrow progenitor cell maintenance and mobilization are modulated by c-kit activity.Circulation Research 107, 1083-1093. [7] Chen, J.F.,Mandel, E.M.,Thomson, J.M.,Wu, Q.,Callis, T.E.,Hammond, S.M.,Conlon, F.L. and Wang, D.Z. (2006)The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation.Nature Genetics 38, 228-233. [8] Chiovaro, F.,Chiquet-Ehrismann, R. and Chiquet, M. (2015)Transcriptional regulation of tenascin genes.Cell Adhesion & Migration 9, 34-47. [9] Christoforou, N.,Chakraborty, S.,Kirkton, R.D.,Adler, A.F.,Addis, R.C. and Leong, K.W. (2017)Core transcription factors, micro-RNAs, and small molecules drive transdifferentiation of human fibroblasts towards the cardiac cell lineage.Scientific Reports 7, 40285. [10] Dai, X.,Wiernek, S.,Evans, J.P. and Runge, M.S. (2016)Genetics of coronary artery disease and myocardial infarction.World Journal of Cardiology 8, 1-23. [11] De Windt, L.J.. and Thum, T. (2015)State-of-the-art on non-coding RNA bioinformatics, diagnostics and therapeutics in cardiovascular diseases: Preface to SI Non-coding RNAs in cardiovascular disease.Journal of Molecular and Cellular Cardiology 89, 1-2. [12] Duflot, T.,Roche, C.,Lamoureux, F.,Guerrot, D. and Bellien, J. (2014)Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases.Expert Opinion on Drug Discovery 9, 229-243. [13] Du, X.,Patel, A.,Anderson, C.S.,Dong, J. and Ma, C.E. (2019)Pidemiology of cardiovascular disease in china and opportunities for improvement: jacc international.Journal of the American College of Cardiology 73, 3135-3147. [14] Fung, E.C.,Butt, A.N.,Eastwood, J.,Swaminathan, R. and Sodi, R. (2019)Circulating microRNA in cardiovascular disease.Advances in Clinical Chemistry 91, 99-122. [15] Gui, Y.J.,Yang, T.,Liu, Q.,Liao, C.X.,Chen, J.Y.,Wang, Y.T.,Hu, J.H. and Xu, D.Y. (2017)Soluble epoxide hydrolase inhibitors, t-AUCB, regulated microRNA-1 and its target genes in myocardial infarction mice.Oncotarget 8, 94635-94649. [16] Gui, Y.,Li, D.,Chen, J.,Wang, Y.,Hu, J.,Liao, C.,Deng, L.,Xiang, Q.,Yang, T.,Du, X.,Zhang, S. and Xu, D. (2018)Soluble epoxide hydrolase inhibitors, t-AUCB, downregulated miR-133 in a mouse model of myocardial infarction.Lipids in Health and Disease 17, 129. [17] Guo, H.,Ingolia, N.T.,Weissman, J.S. and Bartel, D.P. (2010)Mammalian microRNAs predominantly act to decrease target mRNA levels.Nature 466, 835-840. [18] Hagiwara, S.,Kantharidis, P. and Cooper, M.E. (2014)MicroRNA as biomarkers and regulator of cardiovascular development and disease.Current Pharmaceutical Design 20, 2347-2370. [19] Horie, T.,Ono, K.,Nishi, H.,Iwanaga, Y.,Nagao, K.,Kinoshita, M.,Kuwabara, Y.,Takanabe, R.,Hasegawa, K.,Kita, T. and Kimura, T. (2009)MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes.Biochemical and Biophysical Research Communications 389, 315-320. [20] Ikeda, S.,He, A.,Kong, S.W.,Lu, J.,Bejar, R.,Bodyak, N.,Lee, K.H.,Ma, Q.,Kang, P.M.,Golub, T.R. and Pu, W.T. (2009)MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes.Molecular and Cellular Biology 29, 2193-2204. [21] Islas, J.F. and Moreno-Cuevas, J.E. (2018)A MicroRNA Perspective on Cardiovascular Development and Diseases: An Update.International Journal of Molecular Sciences 19, pii:E2075. [22] Katare, R.,Caporali, A.,Zentilin, L.,Avolio, E.,Sala-Newby, G.,Oikawa, A.,Cesselli, D.,Beltrami, A.P.,Giacca, M.,Emanueli, C. and Madeddu, P. (2011)Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling.Circulation Research 108, 1238-1251. [23] Khera, A.V.,Emdin, C.A.,Drake, I.,Natarajan, P.,Bick, A.G.,Cook, N.R.,Chasman, D.I.,Baber, U.,Mehran, R.,Rader, D.J.,Fuster, V.,Boerwinkle, E.,Melander, O.,Orho-Melander, M.,Ridker, P.M. and Kathiresan, S. (2016)Genetic risk, adherence to a healthy lifestyle, and coronary disease.New England Journal of Medicine 375, 2349-2358. [24] Klip, A.,McGraw, T.E. and James, D.E. (2019)Thirty sweet years of GLUT4.Journal of Biological Chemistry 294, 11369-11381. [25] Kwekkeboom, R.F.,Lei, Z.,Doevendans, P.A.,Musters, R.J. and Sluijter, J.P. (2014)Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges.Clinical Science (Lond) 127, 351-365. [26] Lettre, G. (2014)Rare and low-frequency variants in human common diseases and other complex traits.Journal of Medical Genetics 51, 705-714. [27] Lighthouse, J.K. and Small, E.M. (2016)Transcriptional control of cardiac fibroblast plasticity.Journal of Molecular and Cellular Cardiology 91, 52-60. [28] Liu, N.,Bezprozvannaya, S.,Williams, A.H.,Qi, X.,Richardson, J.A.,Bassel-Duby, R. and Olson, E.N. (2008)microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart.Genes & Development 22, 3242-3254. [29] Liu, Q.,Zhao, X.,Peng, R.,Wang, M.,Zhao, W.,Gui, Y.J.,Liao, C.X. and Xu, D.Y. (2017)Soluble epoxide hydrolase inhibitors might prevent ischemic arrhythmias via microRNA-1 repression in primary neonatal mouse ventricular myocytes.Molecular BioSystems 13, 556-564. [30] Losordo, D.W. and Vaughan, D.E. (2014)Going mobile: enhanced recovery from myocardial infarction via stem cell mobilization and homing for tissue repair.Journal of the American College of Cardiology 63, 2873-2874. [31] Lu, H.,Buchan, R.J. and Cook, S.A. (2010)MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism.Cardiovascular Research 86, 410-420. [32] Mikhailov, A.T. and Torrado, M. (2016)Myocardial transcription factors in diastolic dysfunction: clues for model systems and disease.Heart Failure Reviews 21, 783-794. [33] Mikhailov, A. and Chahine, M. (2018)A New Cardiac Channelopathy: From Clinical Phenotypes to Molecular Mechanisms Associated With Nav1.5 Gating Pores.Frontiers in cardiovascular medicine 5, 139. [34] Muraoka, N.,Yamakawa, H.,Miyamoto, K.,Sadahiro, T.,Umei, T.,Isomi, M.,Nakashima, H.,Akiyama, M.,Wada, R.,Inagawa, K. and Nishiyama, T. (2014)MiR-133 promotes cardiac reprogramming by directly repressing Snai1 and silencing fibroblast signatures.The EMBO Journal 33, 1565-1581. [35] Nam, Y.J.,Song, K.,Luo, X.,Daniel, E.,Lambeth, K.,West, K.,Hill, J.A.,DiMaio, J.M.,Baker, L.A.,Bassel-Duby, R. and Olson, E.N. (2013)Reprogramming of human fibroblasts toward a cardiac fate.Proceedings of the National Academy of Sciences of the United States of America 110, 5588-5593. [36] Rasekhi, M.,Soleimani, M.,Bakhshandeh, B. and Sadeghizadeh, M. (2017)A novel protocol to provide a suitable cardiac model from induced pluripotent stem cells.Biologicals: Journal of the International Association of Biological Standardization 50, 42-48. [37] Regulska, K.,Regulski, M.,Karolak, B.,Michalak, M., Murias,M.and Stanisz, B. (2019)Beyond the boundaries of cardiology: Still untapped anticancer properties of the cardiovascular system-related drugs.Pharmacological Research 147, 104326. [38] Samanta, S.,Balasubramanian, S.,Rajasingh, S.,Patel, U.,Dhanasekaran, A.,Dawn, B. and Rajasingh, J. (2016)MicroRNA: A new therapeutic strategy for cardiovascular diseases.Trends in Cardiovascular Medicine 26, 407-419. [39] Schlesinger, J.,Schueler, M.,Grunert, M.,Fischer, J.J.,Zhang, Q.,Krueger, T.,Lange, M.,Tönjes, M.,Dunkel, I. and Sperling, S.R. (2011)The cardiac transcription network modulated by Gata4, Mef2a, Nkx25, Srf, histone modifications, and microRNAs.PLoS Genetics 7, e1001313. [40] Shan, Y.X.,Liu, T.J.,Su, H.F.,Samsamshariat, A.,Mestril, R. and Wang, P.H. (2003)Hsp10 and Hsp60 modulate Bcl-2 family and mitochondria apoptosis signaling induced by doxorubicin in cardiac muscle cells.Journal of Molecular and Cellular Cardiology 35, 1135-1143. [41] Shan, Z.X.,Lin, Q.X.,Deng, C.Y.,Zhu, J.N.,Mai, L.P.,Liu, J.L.,Fu, Y.H.,Liu, X.Y.,Li, Y.X.,Zhang, Y.Y.,Lin, S.G. and Yu, X.Y. (2010)miR-1/miR-206 regulate Hsp60 expression contributing to glucose-mediated apoptosis in cardiomyocytes.FEBS Letters 584, 3592-3600. [42] Shan, Z.X.,Lin, Q.X.,Fu, Y.H.,Deng, C.Y.,Zhou, Z.L.,Zhu, J.N.,Liu, X.Y.,Zhang, Y.Y.,Li, Y.,Lin, S.G. and Yu, X.Y. (2009)Upregulated expression of miR-1/miR-206 in a rat model of myocardial infarction.Biochemical and Biophysical Research Communications 381, 597-601. [43] Shi, Q. and Yang, X. (2016)Circulating microRNA and long noncoding RNA as biomarkers of cardiovascular diseases.Journal of Cellular Physiology 231, 751-755. [44] Staszel, T.,Zapała, B.,Polus, A.,Sadakierska-Chudy, A.,Kieć-Wilk, B.,Stępień, E.,Wybrańska, I.,Chojnacka, M. and Dembińska-Kieć, A. (2011)Role of microRNAs in endothelial cell pathophysiology.Polskie Archiwum Medycyny Wewnętrznej 121, 361-366. [45] Tabet, F.,Vickers, K.C.,Cuesta Torres, L.F.,Wiese, C.B.,Shoucri, B.M.,Lambert, G.,Catherinet, C.,Prado-Lourenco, L.,Levin, M.G.,Thacker, S.,Sethupathy, P.,Barter, P.J.,Remaley, A.T. and Rye, K.A. (2014)HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells.Nature Communications 5, 3292. [46] Thanikachalam, P.V.,Ramamurthy, S.,Wong, Z.W.,Koo, B.J.,Wong, J.Y.,Abdullah, M.F.,Chin, Y.H.,Chia, C.H.,Tan, J.Y.,Neo, W.T.,Tan, B.S.,Khan, W.F. and Kesharwani, P. (2018)Current attempts to implement microRNA-based diagnostics and therapy in cardiovascular and metabolic disease: a promising future.Drug Discovery Today 23, 460-480. [47] Välimäki, M.J. and Ruskoaho, H.J. (2020)Targeting GATA4 for cardiac repair.IUBMB Life 72, 68-79. [48] Valkov, N.,King, M.E.,Moeller, J.,Liu, H.,Li, X. and Zhang, P. (2019)MicroRNA-1-mediated inhibition of cardiac fibroblast proliferation through targeting Cyclin D2 and CDK6.Frontiers in Cardiovascular Medicine 6, 65. [49] Vickers, K.C.,Palmisano, B.T.,Shoucri, B.M.,Shamburek, R.D. and Remaley, A.T. (2011)MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins.Nature Cell Biology 13, 423-433. [50] Wang, Y. and Jin, L. (2018)miRNA-145 is associated with spontaneous hypertension by targeting SLC7A1.Experimental and Therapeutic Medicine 15, 548-552. [51] Wei, Y.,Nazari-Jahantigh, M.,Chan, L.,Zhu, M.,Heyll, K.,Corbalán-Campos, J.,Hartmann, P.,Thiemann, A.,Weber, C. and Schober, A. (2013)The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155-dependent pathway during atherosclerosis.Circulation 127, 1609-1619. [52] Werner, J.H.,Rosenberg, J.H.,Um, J.Y.,Moulton, M.J. and Agrawal, D.K. (2019)Molecular discoveries and treatment strategies by direct reprogramming in cardiac regeneration.Translational Research: the Journal of Laboratory and Clinical Medicine 203, 73-87. [53] Wojciechowska, A.,Braniewska, A. and Kozar-Kamińska, K. (2017)MicroRNA in cardiovascular biology and disease.Advances in Clinical and Experimental Medicine 26, 865-874. [54] Wu, N.,Gu, T.,Lu, L.,Cao, Z.,Song, Q.,Wang, Z.,Zhang, Y.,Chang, G.,Xu, Q. and Chen, G. (2019)Roles of miRNA-1 and miRNA-133 in the proliferation and differentiation of myoblasts in duck skeletal muscle.Journal of Cellular Physiology 234, 3490-3499. [55] Wystub, K.,Besser, J.,Bachmann, A.,Boettger, T. and Braun, T. (2013)miR-1/133a clusters cooperatively specify the cardiomyogenic lineage by adjustment of myocardin levels during embryonic heart development.PLoS Genetics 9, e1003793. [56] Xiao, J.,Luo, X.,Lin, H.,Zhang, Y.,Lu, Y.,Wang, N.,Zhang, Y.,Yang, B. and Wang, Z. (2007)MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts.Journal of Biological Chemistry 282, 12363-12367. [57] Xia, X.D.,Zhou, Z.,Yu, X.H.,Zheng, X.L. and Tang, C.K. (2017)Myocardin: A novel player in atherosclerosis.Atherosclerosis 257, 266-278. [58] Xin, M.,Olson, E.N. and Bassel-Duby, R. (2013)Mending broken hearts: cardiac development as a basis for adult heart regeneration and repair.Nature Reviews Molecular Cell Biology 14, 529-541. [59] Yoon, Y.S.,Uchida, S.,Masuo, O.,Cejna, M.,Park, J.S.,Gwon, H.C.,Kirchmair, R.,Bahlman, F.,Walter, D.,Curry, C.,Hanley, A.,Isner, J.M. and Losordo, D.W. (2005)Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor.Circulation 111, 2073-2085. [60] Yu, X.Y.,Song, Y.H.,Geng, Y.J.,Lin, Q.X.,Shan, Z.X.,Lin, S.G. and Li, Y. (2008)Glucose induces apoptosis of cardiomyocytes via microRNA-1 and IGF-1.Biochemical and Biophysical Research Communications 376, 548-552. [61] Zhang, H.,Fu, Y.,Su, Y.,Shi, Z. and Zhang, J. (2015)Identification and expression of HDAC4 targeted by miR-1 and miR-133a during early development in Paralichthys olivaceus.Comparative Biochemistry and Physiology. Part B, Biochemistry & Molecular Biology 179, 1-8. [62] Zhang, X.G.,Wang, L.Q. and Guan, H.L. (2019)Investigating the expression of miRNA-133 in animal models of myocardial infarction and its effect on cardiac function.European Review for Medical and Pharmacological Sciences 23, 5934-5940. No Suggested Reading articles found! Viewed Full text


Abstract

Cited

  Shared      Discussed